SCHEMBL23219092

SCHEMBL23219092

CCOC(=O)Cc1ccccc1OCc1coc2c(C(F)(F)F)cc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.38
TP53 P04637 2/20 0.37
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
CFD P00746 1/20 0.35
PPARD Q03181 2/20 0.35
MAPT P10636 2/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.34
ALOX5 P09917 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
EPHX2 P34913 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852518 1.00 TBXAS1 (0.38) TBXAS1TP53FFAR1FFAR4MRGPRX4
SCHEMBL23218236 0.88 TSHR (0.36) MAPTPPARGEPHX2KDM4E
SCHEMBL29853153 0.88 TSHR (0.36) MAPTPPARGEPHX2KDM4E
SCHEMBL29852978 0.88 TBXAS1 (0.41) TBXAS1TP53FFAR4CFDMAPT
SCHEMBL23218255 0.88 TBXAS1 (0.41) TBXAS1TP53FFAR4CFDMAPT
SCHEMBL29592551 0.88 TBXAS1 (0.41) TBXAS1TP53FFAR4CFDMAPT
SCHEMBL23218822 0.87 TBXAS1 (0.40) TBXAS1TP53CFDMAPTTHRB
SCHEMBL29853078 0.87 TBXAS1 (0.40) TBXAS1TP53CFDMAPTTHRB
SCHEMBL23218656 0.86 PTGER1 (0.40) TBXAS1TP53CFDMAPTTHRB
SCHEMBL23218880 0.86 TBXAS1 (0.40) TBXAS1TP53MRGPRX4CFDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885TP53 3891/4885FFAR1 3516/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885TP53 3580/4885FFAR1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.